Predicting survival of men with recurrent prostate cancer after radical prostatectomy

To develop and externally validate a novel nomogram aimed at predicting cancer-specific mortality (CSM) after biochemical recurrence (BCR) among prostate cancer (PCa) patients treated with radical prostatectomy (RP) with or without adjuvant external beam radiotherapy (aRT) and/or hormonal therapy (aHT).

The development cohort included 689 consecutive PCa patients treated with RP between 1987 and 2011 with subsequent BCR, defined as two subsequent prostate-specific antigen values >0. 2 ng/ml. Multivariable competing-risks regression analyses tested the predictors of CSM after BCR for the purpose of 5-year CSM nomogram development. Validation (2000 bootstrap resamples) was internally tested. External validation was performed into a population of 6734 PCa patients with BCR after treatment with RP at the Mayo Clinic from 1987 to 2011. The predictive accuracy (PA) was quantified using the receiver operating characteristic-derived area under the curve and the calibration plot method.

The 5-year CSM-free survival rate was 83. 6% (confidence interval [CI]: 79. 6-87. 2). In multivariable analyses, pathologic stage T3b or more (hazard ratio [HR]: 7. 42; p = 0. 008), pathologic Gleason score 8-10 (HR: 2. 19; p = 0. 003), lymph node invasion (HR: 3. 57; p = 0. 001), time to BCR (HR: 0. 99; p = 0. 03) and age at BCR (HR: 1. 04; p = 0. 04), were each significantly associated with the risk of CSM after BCR. The bootstrap-corrected PA was 87. 4% (bootstrap 95% CI: 82. 0-91. 7%). External validation of our nomogram showed a good PA at 83. 2%.

We developed and externally validated the first nomogram predicting 5-year CSM applicable to contemporary patients with BCR after RP with or without adjuvant treatment.

European journal of cancer (Oxford, England : 1990). 2015 Dec 18 [Epub ahead of print]

Paolo Dell'Oglio, Nazareno Suardi, Stephen A Boorjian, Nicola Fossati, Giorgio Gandaglia, Zhe Tian, Marco Moschini, Umberto Capitanio, Pierre I Karakiewicz, Francesco Montorsi, R Jeffrey Karnes, Alberto Briganti

Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada.  Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. , Department of Urology, Mayo Clinic, Rochester, MN, USA. , Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. , Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. , Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada. , Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Department of Urology, Mayo Clinic, Rochester, MN, USA. , Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. , Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada. , Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. , Department of Urology, Mayo Clinic, Rochester, MN, USA. , Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe